Hengrui Medicine launched Ruihengying, a Class 1 innovative biologic long‑acting
insulin injection for adult type 2 diabetes, on Alibaba Health. The product —
China’s first domestically developed long‑acting insulin analog — moved from
regulatory approval to online listing in one month; industry participants say
this signals a shortening of the approval‑to‑market chain for innovative drugs
in China.